Drug Profile
Research programme: haemophilia B therapeutics - Wyeth/Nautilus
Latest Information Update: 06 Oct 2011
Price :
$50
*
At a glance
- Originator Nautilus Biotech; Wyeth
- Class
- Mechanism of Action Factor IX stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemophilia B
Most Recent Events
- 12 Aug 2009 No development reported - Preclinical for Haemophilia B in France (Parenteral)
- 08 Feb 2007 Preclinical trials in Haemophilia B in France (Parenteral)